Skip to main content

Table 4 Surgical outcomes and complications

From: Risks and complications of transurethral resection of bladder tumors in patients receiving antiplatelet and/or anticoagulant therapy: a retrospective cohort study

 

AP/AC

  

Continuation (A)

n = 19, n (%)

Interruption (B)

n = 18, n (%)

Control (C)

n = 137, n (%)

 

p value

 

A vs B

A vs C

B vs C

Median Hb decrease

g/dL (range)

−0.5

(−−2.8–0.6)

−0.4

(−1.6–1.2)

−0.5

(−3.1–2.6)

0.27

0.20

0.48

Median catheter indwelling days (range)

2

(1–8)

1

(1–5)

1

(0–20)

0.06

0.03

0.50

Clot retention

4

(21)

0

(0)

7

(5)

0.11

0.03

>0.95

Surgical reintervention

2

(11)

0

(0)

3

(2)

0.49

0.11

>0.95

Transfusion

0

(0)

0

(0)

2

(1)

>0.95

>0.95

>0.95

Cardiovascular events

0

(0)

0

(0)

0

(0)

>0.95

>0.95

>0.95

Median days of hospital stay after surgery (range)

5

(3–12)

5

(3–7)

5

(2–14)

0.57

0.18

0.50

Re-admission

0

(0)

0

(0)

0

(0)

>0.95

>0.95

>0.95

  1. AP antiplatelet agents, AC anticoagulant agents, Hb hemoglobin